BiotechTube
Home/Pipeline/Vunakizumab (XmAb®2513)

Vunakizumab (XmAb®2513)

Autoimmune Diseases

Phase 1Active

Key Facts

Indication
Autoimmune Diseases
Phase
Phase 1
Status
Active
Company
Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

OncologyAutoimmune DisordersInfectious Disease

Other Autoimmune Diseases Drugs

DrugCompanyPhase
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Gavocabtagene autoleucelAstellasPhase 1/2
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial
I&I PortfolioThird Arc BioPre-clinical
Undisclosed Platform ProgramsZag BioPreclinical
E-602Palleon PharmaceuticalsIND-Enabling
DIASPOT Platform ExpansionDIAsource ImmunoAssaysCommercial & Development